Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 9 March 2017, 11:00 HKT/SGT

Source: Novotech
New Research reveals Asia poised as Preferred Destination for Clinical Trials

SYDNEY, Mar 9, 2017 - (ACN Newswire) - Frost & Sullivan has released a white paper, 'Asia: Preferred Destination for Clinical Trials', with Asia Pacific CRO Novotech presenting the findings to an audience of senior biotechnology and pharmaceutical executives in a private event at the Outsourcing in Clinical Trials - West Coast (OCT-WC 2017) conference, held Feb 22-23 in Burlingame, Ca. (USA).

Research from the paper revealed Asia as quickly becoming a clinical research powerhouse, facilitated by the availability of vast treatment-naive patient pools, exceptional clinical infrastructure and talent, and low operational costs.

- Resources, Capabilities and Speed

Elements unique to Asia include large treatment-naive patient pools, numerous clinical trial centres with advanced equipment and technology, and comparable incidence and prevalence of Western diseases. The region's knowledgeable physicians and Key Opinion Leaders (KOLs) provide attractive environments for clinical trials and facilitate speedy trials; while low healthcare spend by many governments in Asia make clinical trials an attractive way for patients to access innovative therapies in these countries.

- Worldwide Data Acceptability

Data from clinical trials in Asia is routinely accepted as part of US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) regulatory submissions. KOLs from Asia are often members of international expert groups and citable academic output from Asia is growing rapidly. Data from inspections conducted in Asia by US FDA and EMA show low levels of adverse findings versus the US or European Union (EU), indicating high international compliance to standards.

- Cost-Effectiveness

Costs in Asia for procedures, diagnostic tests and visits are generally 30-40% lower than the US and European countries.

The paper cautioned on regulatory differences in Asia, the variety of infrastructure and legal issues, and the language and cultural hurdles, but concluded that as transparency in the regulatory environment in Asia improves, the region was poised to become the preferred destination for clinical trials.

Commenting on the paper, Novotech CEO Dr. John Moller said, "Asia is an increasingly attractive destination for our biotech clients. The huge patient pools available in Asia are mainly concentrated in easily accessible urban areas, meaning that trials tend to recruit faster. In addition, the cost of trials in most Asian countries is significantly lower than the West.

"Now is an exciting time for clinical trials taking place in Asia. There are a number of large, state-of-the-art clinical trial centers in Asia that meet patient enrolment and retention goals, generate high-quality data, and are led by globally recognised key opinion leaders," added Dr. Moller. "Regulatory processes in Asia continue to become more streamlined. Novotech is actively working with a number of regulatory authorities and clinical trial centres to improve approval processes and timelines."

Download the Frost & Sullivan white paper 'Asia: Preferred Destination for Clinical Trials', available as Executive Summary ( or Full Paper (

About Novotech

Headquartered in Sydney, Novotech is internationally recognised as the leading full-service contract research organisation (CRO) in the region. With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I-IV clinical trials across Asia-Pacific, and provides clinical development services for all clinical trial phases and therapeutic areas, running clinical trials in every key regional market. For more information, please visit

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. To learn more, please visit

Please contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
T: +61 2 8218 2144 / +1 650 798 5238

Mar 9, 2017 11:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: HealthCare
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

June 15, 2018 16:30 HKT/SGT
Novotech signs MoU with CMUH Taiwan to offer Enhanced Services for Global Trials
June 12, 2018 11:00 HKT/SGT
Novotech Signs MOU with China Medical University Hospital in Taiwan to Offer Enhanced Services for Global Trials
May 18, 2018 02:00 HKT/SGT
Novotech says Federal Budget R&D Tax Support Keeps Australia Globally Competitive for Quality Clinical Trials
June 23, 2017 08:00 HKT/SGT
Novotech signs Central Lab Services Agreement with Sonic Clinical Trials
Apr 18, 2017 10:00 HKT/SGT
Novotech signs MOU with South Korea's leading medical center, the Asan Medical Center
Mar 3, 2017 14:00 HKT/SGT
New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: